Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modified FOLFOX 6 and Cetuximab in First Line Treatment of Metastatic Colorectal Cancer
NCT00251485Phase 2Completed
- Sponsor
- Veeda Lifesciences
- Start
- Mar 2004
- Primary completion
- Jun 2005
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of KL-140 in colorectal cancer (CRC), sponsored by Veeda Lifesciences. Primary endpoints: Objective Response Rate, Progression-Free Survival and 1 more. Started Mar 2004; status: completed.
02
Drugs
KL-140
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00251485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00251485.